Shares of Omnicell, Inc. (NASDAQ:OMCL) have earned an average rating of “Buy” from the eleven brokerages that are covering the stock, MarketBeat reports. Three equities research analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 1 year price target among analysts that have covered the stock in the last year is $51.86.

Several analysts have commented on the company. Oppenheimer Holdings, Inc. reaffirmed a “buy” rating and set a $55.00 price objective on shares of Omnicell in a research note on Thursday. Benchmark Co. upped their price objective on Omnicell from $55.00 to $67.00 and gave the company a “buy” rating in a research note on Tuesday, September 5th. BidaskClub downgraded Omnicell from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Piper Jaffray Companies reaffirmed a “hold” rating and set a $40.00 price objective on shares of Omnicell in a research note on Sunday, July 30th. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and set a $47.00 price objective on shares of Omnicell in a research note on Tuesday, July 25th.

ILLEGAL ACTIVITY NOTICE: “Omnicell, Inc. (OMCL) Receives Average Recommendation of “Buy” from Brokerages” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/10/22/omnicell-inc-omcl-receives-average-recommendation-of-buy-from-brokerages-2.html.

Omnicell (NASDAQ:OMCL) traded up 2.68% during mid-day trading on Friday, reaching $53.55. The company had a trading volume of 204,904 shares. Omnicell has a 12 month low of $30.35 and a 12 month high of $55.00. The company’s market capitalization is $2.01 billion. The firm’s 50 day moving average price is $50.70 and its 200-day moving average price is $45.53.

Omnicell (NASDAQ:OMCL) last posted its earnings results on Thursday, July 27th. The company reported $0.02 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.02. The business had revenue of $180.90 million during the quarter, compared to the consensus estimate of $174.08 million. Omnicell had a positive return on equity of 0.41% and a negative net margin of 1.14%. The business’s quarterly revenue was up 4.6% on a year-over-year basis. During the same period in the previous year, the business earned $0.38 EPS. Equities research analysts anticipate that Omnicell will post $1.30 earnings per share for the current year.

In other news, Chairman Randall A. Lipps sold 40,000 shares of the stock in a transaction that occurred on Tuesday, August 1st. The stock was sold at an average price of $49.76, for a total transaction of $1,990,400.00. Following the completion of the transaction, the chairman now directly owns 196,551 shares of the company’s stock, valued at approximately $9,780,377.76. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Chairman Randall A. Lipps sold 37,500 shares of the stock in a transaction that occurred on Friday, July 28th. The stock was sold at an average price of $46.00, for a total value of $1,725,000.00. Following the transaction, the chairman now directly owns 196,551 shares of the company’s stock, valued at $9,041,346. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 184,094 shares of company stock valued at $9,094,791. 3.77% of the stock is owned by company insiders.

Hedge funds have recently modified their holdings of the company. Ameritas Investment Partners Inc. purchased a new position in shares of Omnicell during the 1st quarter worth approximately $125,000. Oppenheimer Asset Management Inc. purchased a new position in shares of Omnicell during the 1st quarter worth approximately $170,000. Turner Investments LLC purchased a new position in shares of Omnicell during the 2nd quarter worth approximately $181,000. Flinton Capital Management LLC raised its stake in shares of Omnicell by 74.6% during the 2nd quarter. Flinton Capital Management LLC now owns 4,216 shares of the company’s stock worth $182,000 after buying an additional 1,802 shares in the last quarter. Finally, Riverhead Capital Management LLC raised its stake in shares of Omnicell by 76.3% during the 2nd quarter. Riverhead Capital Management LLC now owns 4,230 shares of the company’s stock worth $182,000 after buying an additional 1,830 shares in the last quarter.

About Omnicell

Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.

Analyst Recommendations for Omnicell (NASDAQ:OMCL)

Receive News & Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related companies with MarketBeat.com's FREE daily email newsletter.